143 related articles for article (PubMed ID: 36054637)
1. Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Zhao X; Li X; Lin Y; Ma R; Zhang Y; Xu D; Li Y
Cancer Med; 2023 Feb; 12(3):2637-2645. PubMed ID: 36054637
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Su YD; Zhao X; Ma R; Fu YB; Yang ZR; Wu HL; Yu Y; Yang R; Liang XL; Du XM; Chen Y; Li Y
Int J Hyperthermia; 2023; 40(1):2223374. PubMed ID: 37348853
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
4. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
9. [The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):419-424. PubMed ID: 32482033
[No Abstract] [Full Text] [Related]
10. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival in patients with PMP: a single-institutional retrospective study from China.
Yang R; Fu YB; Li XB; Ma R; Su YD; Wu HL; Liang XL; Li Y
World J Surg Oncol; 2023 Oct; 21(1):347. PubMed ID: 37891655
[TBL] [Abstract][Full Text] [Related]
12. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
13. Effect of standardized fluid management on cardiac function after CRS + HIPEC in patients with PMP: a single-center case-control study.
Yang R; Su YD; Liu G; Yu Y; Li XB; Zhao X; Ji ZH; Ma R; Yang ZR; Lin YL; Wu HL; Li Y
Int J Hyperthermia; 2023; 40(1):2182749. PubMed ID: 36889694
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
[TBL] [Abstract][Full Text] [Related]
15. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
[TBL] [Abstract][Full Text] [Related]
18. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.
Trilling B; Brind'Amour A; Hamad R; Tremblay JF; Dubé P; Mitchell A; Sidéris L
World J Surg Oncol; 2021 Feb; 19(1):60. PubMed ID: 33622339
[TBL] [Abstract][Full Text] [Related]
19. [Surgical treatment of pseudomyxoma peritonei-Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Wahba R; Schmidt T; Buchner D; Wagner T; Bruns CJ
Chirurgie (Heidelb); 2023 Oct; 94(10):840-844. PubMed ID: 37578542
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
